In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Varian's "smart" imaging tool:

This article was originally published in Clinica

Executive Summary

Varian Medical Systems has received FDA 510(k) clearance for its Smart Segmentation technology, a radiotherapy treatment planning tool. It is designed to enable clinicians to reduce the amount of time needed to plan treatments including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), brachytherapy, and proton therapy. The Palo Alto, California firm claims that the new Smart Segmentation feature, which has been added to Varian's Eclipse treatment planning product, is the world's first fully automatic tool that uses intelligent software to identify organs and other structures within diagnostic images of the thorax and male pelvis. The Smart Segmentation tool can automatically identify all of the structures of interest in less than 45 seconds. Previously, structures requiring radiotherapy or protection from radiotherapy had to be identified manually.

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

MT049498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel